FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008025218> ?p ?o ?g. }

• W2008025218 endingPage "33690" @default.
• W2008025218 startingPage "33684" @default.
• W2008025218 abstract "RIP2 is a serine-threonine kinase associated with the tumor necrosis factor (TNF) receptor complex and is implicated in the activation of NF-κB and cell death in mammalian cells. However, the function of its kinase domain is still enigmatic as it is not required in engaging these responses. Here we show that RIP2 activates the extracellular signal-regulated kinase (ERK) pathway and that the kinase activity of RIP2 appears to be important in this process. RIP2 activates AP-1 and serum response element regulated expression by inducing the activation of the Elk1 transcription factor. RIP2 directly phosphorylates and activates ERK2 in vivo and in vitro. RIP2 in turn is activated through its interaction with Ras-activated Raf1. Kinase-defective point and deletion variants of RIP2 also significantly blocked the activation of ERK2 by TNFα but not epidermal growth factor. These results describe a novel pathway of ERK activation and the first catalytic function ascribed to any of the RIP-like kinases associated with the TNF receptor superfamily. RIP2 is a serine-threonine kinase associated with the tumor necrosis factor (TNF) receptor complex and is implicated in the activation of NF-κB and cell death in mammalian cells. However, the function of its kinase domain is still enigmatic as it is not required in engaging these responses. Here we show that RIP2 activates the extracellular signal-regulated kinase (ERK) pathway and that the kinase activity of RIP2 appears to be important in this process. RIP2 activates AP-1 and serum response element regulated expression by inducing the activation of the Elk1 transcription factor. RIP2 directly phosphorylates and activates ERK2 in vivo and in vitro. RIP2 in turn is activated through its interaction with Ras-activated Raf1. Kinase-defective point and deletion variants of RIP2 also significantly blocked the activation of ERK2 by TNFα but not epidermal growth factor. These results describe a novel pathway of ERK activation and the first catalytic function ascribed to any of the RIP-like kinases associated with the TNF receptor superfamily. extracellular signal-regulated kinase mitogen-activated protein kinase tumor necrosis factor TNF receptor epidermal growth factor TNF-receptor-associated factors caspase-recruiting domain Chinese hamster ovary polyacrylamide gel electrophoresis myelin basic protein 4-morpholinepropanesulfonic acid c-Jun N-terminal kinase MAPK/ERK kinase mitogen-activated protein glutathioneS-transferase serum response element green fluorescent protein The ERK1/MAPK signaling pathway is critical for a number of biological processes including proliferation and differentiation (1Lewis T.S. Shapiro P.S. Ahn N.G. Adv. Cancer Res. 1998; 74: 49-139Crossref PubMed Google Scholar, 2Robinson M.J. Cobb M.H. Curr. Opin. Cell Biol. 1997; 9: 180-186Crossref PubMed Scopus (2278) Google Scholar). The ERKs can be activated by a variety of ligands including growth factors such as EGF and cytokines such as TNFα (3Boulton T.G. Nye S.H. Robbins D.J. Ip N.Y. Radziejewska E. Morgenbesser S.D. DePinho R.A. Panayotatos N. Cobb M.H. Yancopoulos G.D. Cell. 1991; 65: 663-675Abstract Full Text PDF PubMed Scopus (1482) Google Scholar, 4Belka C. Wiegmann K. Adam D. Holland R. Neulloh M. Hermann F. Kronke M. Brach M.A. EMBO J. 1995; 14: 1156-1165Crossref PubMed Scopus (91) Google Scholar, 5Winston B.W. Riches D.W. J. Immunol. 1995; 155: 1525-1533PubMed Google Scholar, 6Winston B.W. Lange-Carter C.A. Gardner A.M. Johnson G.L. Riches D.W. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 1614-1618Crossref PubMed Scopus (134) Google Scholar). In response to EGF, Ras becomes activated by a guanylate exchange reaction, and GTP-Ras recruits Raf1 to the membrane where Raf1 is activated by mechanisms that may involve phosphorylation and conformational changes (7Leevers D.J. Paterson H.F. Marshall C.J. Nature. 1994; 369: 411-414Crossref PubMed Scopus (881) Google Scholar, 8Morrison D.K. Cutler R.E. Curr. Opin. Cell Biol. 1997; 9: 174-179Crossref PubMed Scopus (534) Google Scholar, 9Stokoe D. MacDonald S.G. Cadwallader K. Symons M. Hancock J.F. Science. 1994; 264: 1463-1467Crossref PubMed Scopus (840) Google Scholar). Active Raf1 phosphorylates MEK1 which in turn phosphorylates and activates the ERKs (10Marshall C.J. Cell. 1995; 80: 179-185Abstract Full Text PDF PubMed Scopus (4225) Google Scholar). However, the mechanism by which TNFα activates the ERKs is less well understood. TNFα binds two distinct cell surface receptors, TNFR1 (55 kDa) or TNFR2 (75 kDa) (11Vandenabelee P. Declercg W. Beyaert R. Fiers W. Trends Cell Biol. 1995; 5: 392-399Abstract Full Text PDF PubMed Scopus (735) Google Scholar). Whereas TNFR2 binds TNFα more tightly, TNFR1 is thought to be the predominant receptor that signals both cytotoxic and inflammatory responses. The cytoplasmic domains of these receptors do not possess any catalytic activity although they do contain binding sites for other receptor-associated proteins that mediate the signaling responses triggered by TNFα (12Beutler B. Van Huffel C. Science. 1994; 264: 667-668Crossref PubMed Scopus (420) Google Scholar, 13Smith C.A. Farrah T. Goodwin R.G. Cell. 1994; 76: 959-962Abstract Full Text PDF PubMed Scopus (1835) Google Scholar). The intracellular mediators of the TNFα response include proteins characterized by “death domains” such as TRADD (14Hsu H.L. Xiong J. Goeddel D.V. Cell. 1995; 81: 495-504Abstract Full Text PDF PubMed Scopus (1739) Google Scholar), FADD/MORTI (15Chinnaiyan A.M. O'Rourke K. Tewari M. Dixit V.M. Cell. 1995; 81: 505-512Abstract Full Text PDF PubMed Scopus (2154) Google Scholar), RIP (16Hsu H.L. Huang J.N. Shu H.B. Baichwal V. Goeddel D.V. Immunity. 1996; 4: 387-396Abstract Full Text Full Text PDF PubMed Scopus (977) Google Scholar, 17Stanger B.Z. Leder P. Lee T.H. Kim E. Seed B. Cell. 1995; 81: 513-523Abstract Full Text PDF PubMed Scopus (861) Google Scholar), and RAIDD (18Duan H. Dixit V.M. Nature. 1997; 385: 86-89Crossref PubMed Scopus (469) Google Scholar). These proteins bind a conserved 80-amino acid region found in the cytoplasmic domain of TNFR receptor family members and serve as adaptors to assemble a signaling complex that leads to apoptosis (19Ashkenazi A. Dixit V.M. Science. 1998; 281: 1305-1308Crossref PubMed Scopus (5127) Google Scholar). Another group of receptor-interacting molecules includes the TNF receptor-associated factors (TRAFs; reviewed in Ref. 20Arch R.H. Gedrich R.W. Thompson C.B. Genes Dev. 1998; 12: 2821-2830Crossref PubMed Scopus (512) Google Scholar). Upon TNFR-1 trimerization, TNFR-1 binds TRADD that recruits FADD, RIP, and TRAF2 (16Hsu H.L. Huang J.N. Shu H.B. Baichwal V. Goeddel D.V. Immunity. 1996; 4: 387-396Abstract Full Text Full Text PDF PubMed Scopus (977) Google Scholar). FADD initiates apoptosis by mediating the activation of caspase-8 (21Boldin M.P. Goncharov T.M. Goltsev Y.V. Wallach D. Cell. 1996; 85: 803-815Abstract Full Text Full Text PDF PubMed Scopus (2104) Google Scholar, 22Chinnaiyan A.M. Tepper C.G. Seldin M.F. O'Rouke K. Kischkel F.C. Hellbardt S. Krammer P.H. Peter M.E. Dixit V.M. J. Biol. Chem. 1996; 271: 4961-4965Abstract Full Text Full Text PDF PubMed Scopus (706) Google Scholar, 23Hsu H.L. Shu H.B. Pan M.G. Goeddel D.V. Cell. 1996; 84: 299-308Abstract Full Text Full Text PDF PubMed Scopus (1728) Google Scholar, 24Muzio M. Chinnaiyan A.M. Kischkel F.C. O'Rouke K. Shevchenko A. Ni J. Scaffidi C. Bretz J.D. Zhang M. Gentz R. Mann M. Krammer P.H. Peter M.E. Dixit V.M. Cell. 1996; 85: 817-827Abstract Full Text Full Text PDF PubMed Scopus (2730) Google Scholar). RIP appears to mediate NF-κB activation (25Kelliher M.A. Grimm S. Ishida Y. Kuo F. Stanger B.Z. Leder P. Immunity. 1998; 8: 297-303Abstract Full Text Full Text PDF PubMed Scopus (918) Google Scholar, 26Ting A.T. Pimentel-Muinos F.X. Seed B. EMBO J. 1996; 15: 6189-6196Crossref PubMed Scopus (468) Google Scholar), whereas TRAF2 activates JNK (27Lee S.Y. Reichlin A. Santana A. Sokol K.A. Nussenzweig M.C. Choi Y. Immunity. 1997; 7: 703-713Abstract Full Text Full Text PDF PubMed Scopus (403) Google Scholar, 28Reinhard C. Shamoon B. Shymala V. Williams L.T. EMBO J. 1997; 16: 1080-1092Crossref PubMed Scopus (252) Google Scholar, 29Yeh W.C. Shahinian A. Speiser D. Kraunus J. Billia F. Wakeham A. de la Pomopa J.L. Ferrick D. Hum B. Iscove N. Ohashi P. Rothe M. Goeddel D.V. Mak T.W. Immunity. 1997; 7: 715-725Abstract Full Text Full Text PDF PubMed Scopus (712) Google Scholar). Although RIP is an active serine-threonine kinase, the functional significance of its kinase activity is still unknown since it is not essential for NF-κB activation and apoptosis (16Hsu H.L. Huang J.N. Shu H.B. Baichwal V. Goeddel D.V. Immunity. 1996; 4: 387-396Abstract Full Text Full Text PDF PubMed Scopus (977) Google Scholar). In addition to the activation of JNK and induction of apoptosis, TNFα also activates the ERK pathway. However, Raf1 activation, which is a key step in ERK activation by receptor tyrosine kinases, has been observed in response to TNFα only in some (4Belka C. Wiegmann K. Adam D. Holland R. Neulloh M. Hermann F. Kronke M. Brach M.A. EMBO J. 1995; 14: 1156-1165Crossref PubMed Scopus (91) Google Scholar, 30Huwiler A. Brunner J. Hummel R. Vervoordeldonk M. Stable S. Vanden Bosch H. Pfeilschifter K. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 6959-6963Crossref PubMed Scopus (184) Google Scholar, 31Yao B. Zhang Y. Delikat S. Mathias S. Basu S. Kolesnick R. Nature. 1995; 378: 307-310Crossref PubMed Scopus (303) Google Scholar, 32Zhang Y. Yao B. Delikat S. Bayoumy S. Lin X.H. Basu S. McGinley M. Chan-Hui P.Y. Lichenstein H. Kolesnick R. Cell. 1997; 89: 63-72Abstract Full Text Full Text PDF PubMed Scopus (390) Google Scholar) but not all reports (6Winston B.W. Lange-Carter C.A. Gardner A.M. Johnson G.L. Riches D.W. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 1614-1618Crossref PubMed Scopus (134) Google Scholar, 33Muller G. Storz P. Bourteele S. Doppler H. Pfizenmaier K. Mischak H. Philipp A. Kaiser C. Kolch W. EMBO J. 1998; 17: 732-742Crossref PubMed Scopus (104) Google Scholar, 34Westwick J.K. Weitzel C. Minden A. Karin M. Brenner D.A. J. Biol. Chem. 1994; 269: 26396-26401Abstract Full Text PDF PubMed Google Scholar). Recently, the TNF receptor has been found to interact with the adaptor protein Grb2 and the exchange factor SOS in response to TNFα (35Hildt E. Oess S. J. Exp. Med. 1999; 189: 1707-1714Crossref PubMed Scopus (64) Google Scholar). In other circumstances, these interactions lead to Ras and Raf1 activation, but in response to TNFα, it may not be sufficient for ERK activation. An alternative derives from the observation that TNFα induces neutral and acidic sphingomyelinases that convert sphingomyelin to the secondary messenger, ceramide (reviewed in Ref. 36Hannun Y.A. Science. 1996; 274: 1855-1859Crossref PubMed Scopus (1491) Google Scholar). It has been reported that ceramide produced by neutral sphingomyelinase activates the ERK pathway through the sequential activation of ceramide-activated protein kinase and Raf1 (4Belka C. Wiegmann K. Adam D. Holland R. Neulloh M. Hermann F. Kronke M. Brach M.A. EMBO J. 1995; 14: 1156-1165Crossref PubMed Scopus (91) Google Scholar,31Yao B. Zhang Y. Delikat S. Mathias S. Basu S. Kolesnick R. Nature. 1995; 378: 307-310Crossref PubMed Scopus (303) Google Scholar). In apparent contrast to these results, Muller et al.(33Muller G. Storz P. Bourteele S. Doppler H. Pfizenmaier K. Mischak H. Philipp A. Kaiser C. Kolch W. EMBO J. 1998; 17: 732-742Crossref PubMed Scopus (104) Google Scholar) demonstrated that ceramide directly binds Raf1, but this interaction leads to the formation of an inactive complex with GTP-Ras. Thus, whereas ERK activation is known to be a direct consequence of TNF stimulation by TNFR1 and TNFR2, the mediation through Raf1 is still uncertain. Recently, three groups reported the isolation of a novel serine-threonine kinase RIP2 (also known as RICK or CARDIAK) (37Inohara N. del Peso L. Koseki T. Chen S. Nunez G. J. Biol. Chem. 1998; 273: 12296-12300Abstract Full Text Full Text PDF PubMed Scopus (216) Google Scholar, 38McCarthy J.V. Ni J. Dixit V. J. Biol. Chem. 1998; 273: 16968-16975Abstract Full Text Full Text PDF PubMed Scopus (361) Google Scholar, 39Thome M. Hofmann K. Burns K. Martinon F. Bodmer J.L. Mattmann C. Tschopp J. Curr. Biol. 1998; 8: 885-888Abstract Full Text Full Text PDF PubMed Google Scholar). RIP2 is homologous to RIP and interacts with members of the TNFR-1, CD40, and Fas signaling complexes, in particular with TRAF1, TRAF5, TRAF6 (38McCarthy J.V. Ni J. Dixit V. J. Biol. Chem. 1998; 273: 16968-16975Abstract Full Text Full Text PDF PubMed Scopus (361) Google Scholar), and TRAF2 (39Thome M. Hofmann K. Burns K. Martinon F. Bodmer J.L. Mattmann C. Tschopp J. Curr. Biol. 1998; 8: 885-888Abstract Full Text Full Text PDF PubMed Google Scholar). RIP2 contains an N-terminal kinase domain and a C-terminal caspase-recruiting domain (CARD) domain that binds CLARP, caspase-1, and caspase-8. RIP2 can activate NF-κB and can induce apoptosis, although none of these activities was shown to be dependent on the kinase activity of RIP2. We independently isolated RIP2 and show here that RIP2 kinase activity directly activates ERK1/2 and appears to mediate TNF-dependent ERK activation. These results describe a novel pathway of ERK activation and the first catalytic function ascribed to any of the RIP-like kinases associated with the TNF receptor superfamily. RIP2 was cloned from a human fetal lung cDNA library in pRK vector using standard hybridization methods. The oligonucleotides used for screening were designed from an EST sequence homologous to Raf1 which was obtained from the Incyte data base. An oligonucleotide encoding the FLAG epitope (DYKDDDDK) was cloned in frame to the N terminus to generate FLAG-RIP2. FLAG-RIP2(D146A) was generated by in vitro mutagenesis (Stratagene) and confirmed by DNA sequencing and Western analysis. COS-7 and 293 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 2 nml-glutamine, 100 units/ml penicillin, and 100 μg/ml streptomycin. CHO cells were maintained in F-12/Dulbecco's modified Eagle's medium (provided by C. Crowley, Genentech, Inc.) containing 5% fetal calf serum, 50 units/ml penicillin, and 50 μg/ml streptomycin. Transient transfections were all carried out using Superfect (Qiagen) according to manufacturer's instructions. For Pathdetect and Luciferase reporter assays, 2 × 105 cells on 6-well (35-mm) dishes were used. For co-immunoprecipitations and kinase assays, 2 × 106cells were seeded on 100-mm dishes. Expression plasmids pUSE-Ras, pUSE-Ras(L61Q), pUSE-RasN17, pUSE-Raf1, and pUSE-ERK2 were purchased from Upstate Biotechnology, Inc. Human recombinant TNFα and EGF were from R & D Systems. RIP2 deletion plasmids (311–541) and (455–541) were provided by J. McCarthy and V. M. Dixit (38McCarthy J.V. Ni J. Dixit V. J. Biol. Chem. 1998; 273: 16968-16975Abstract Full Text Full Text PDF PubMed Scopus (361) Google Scholar). Raf1(K375M) was generated by subcloning Raf1 into pRK5D and performing in vitro mutagenesis using the Gene Editor System (Promega). Mutagenesis was confirmed by DNA sequencing and Western analysis. In vivo c-Jun and Elk1 phosphorylation was determined using the Pathdetect c-Jun and Elk1 Trans-Reporting Systems (Stratagene). Reporter plasmids pFR-Luc, pAP1-Luc, and pSRE-Luc were from Stratagene, and pRL-TK was from Promega. Firefly and Renilla luciferase assays were performed using the Dual-Luciferase Reporter assay system (Promega). The fold induction of luciferase expression is calculated by obtaining the ratios of firefly luciferase to Renilla luciferase units for each gene and dividing the result with that of the vector control. Transiently transfected cells (100-mm dishes) were lysed in Co-IP buffer (200 mm Hepes, pH 7.4, 1% Triton X-100, 100 mmNaCl, 2 mm EDTA, 10 mm NaF, 10 mmsodium pyrophosphate, and 2 mm orthovanadate) containing complete protease inhibitors (Roche Molecular Biochemicals). Samples were immunoprecipitated overnight at 4 °C with either anti-Raf1 agarose-conjugated antibodies (Santa Cruz Biotechnology) or anti-FLAG M2 affinity beads (IBI, Eastman Kodak Co.). Immunoprecipitates were washed three times in lysis buffer, resolved by SDS-PAGE, transferred onto a nitrocellulose membrane (Novex), and immunoblotted using rabbit polyclonal anti-FLAG (IBI Kodak), anti-Raf1, anti-Ras (Santa Cruz Biotechnology), anti-phosphoprotein antibodies (Zymed Laboratories Inc.), or with phospho-specific p44/42 MAP kinase (T202/Y212) antibody (Promega or NEB) and then visualized using the ECL system (Pierce). Unless otherwise indicated all results were reproduced in at least two independent experiments. Transfected cells were lysed and immunoprecipitated in RIPA buffer (phosphate-buffered saline containing 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS and protease inhibitor mixture) with rabbit polyclonal agarose-conjugated anti-ERK2 (Santa Cruz Biotechnology), anti-FLAG, or anti-Raf1 antibodies. Immunoprecipitates were washed three times with lysis buffer and once with kinase wash buffer (50 mm Tris-HCl, 15 mmMgCl2). Kinase assays were performed at 30 °C for 30 min in 30 μl of Assay Dilution Buffer (20 mm MOPS, pH 7.2, 25 mm β-glycerol phosphate, 5 mm EGTA, 1 mm sodium orthovanadate, 1 mm dithiothreitol, 6.5 mm MgCl2, and 5 μm ATP) (Upstate Biotechnology, Inc.) containing 20 μm protein kinase C inhibitor peptide, 2 μm protein kinase A inhibitor peptide, and 20 μm calmodulin inhibitor (compound R24571) and supplemented with 100 mm[γ-32P]ATP (Amersham Pharmacia Biotech). ERK2 activity was assayed by using 2.0 μg of MBP substrate (Upstate Biotechnology, Inc.). To assay for RIP2 activity, 0.5 μg of purified uninduced ERK2 (Upstate Biotechnology, Inc.) was added with MBP. To assay for Raf1 activity, 0.5 μg of purified uninduced MEK1, 0.5 μg of ERK2, and 2 μg of MBP were added to the reaction. Alternative substrates used include 1.0 μg of GST-ERK1 (K71A) (Upstate Biotechnology, Inc.) and 2.0 μg of poly-His-MEK1 (Santa Cruz Biotechnology). Stress-activated protein kinase/Jun NH2-terminal kinase activity was assayed using materials and protocols provided by Bio-Rad. Unless otherwise indicated, all results were reproduced in at least two independent experiments. In a search for additional kinases that could be implicated in the MAP kinase pathway, we searched EST data bases and identified an open reading frame that has significant homology to the kinase domain of Raf1. By using the EST sequence, we isolated a novel full-length human cDNA that contains a 1623-base pair open reading frame, encodes 540 amino acid residues, and has a predicted molecular mass of about 60 kDa. While this work was in preparation, the cloning and pro-apoptotic activity of this kinase was reported by three other groups (37Inohara N. del Peso L. Koseki T. Chen S. Nunez G. J. Biol. Chem. 1998; 273: 12296-12300Abstract Full Text Full Text PDF PubMed Scopus (216) Google Scholar, 38McCarthy J.V. Ni J. Dixit V. J. Biol. Chem. 1998; 273: 16968-16975Abstract Full Text Full Text PDF PubMed Scopus (361) Google Scholar, 39Thome M. Hofmann K. Burns K. Martinon F. Bodmer J.L. Mattmann C. Tschopp J. Curr. Biol. 1998; 8: 885-888Abstract Full Text Full Text PDF PubMed Google Scholar). In accordance with the earlier published nomenclature and because of its extensive homology to both the kinase and intermediate domains of RIP (21% identity), we refer to the kinase we report here as RIP2. In addition to having high homology with the RAF family of kinases (24% identity), the kinase domain of RIP2 also contains two TEY motifs (amino acid residues 95–97 and 111–113) which are conserved in the ERK family of kinases but are not found in RIP. All MAPKs contain signature TXY motifs within the activating phosphorylation site, and the X residue distinguishes the three subfamilies of MAPKs (ERK, JNK, and p38) (40Davis R.J. Trends Biochem. Sci. 1994; 19: 470-473Abstract Full Text PDF PubMed Scopus (917) Google Scholar). We therefore determined whether RIP2 can activate any of the MAP kinase pathways. We examined whether expression of RIP2 in a heterologous system can stimulate the transcription of a luciferase reporter controlled by promoters containing either AP-1 or SRE elements. The AP-1 complex is composed of members of the c-Jun and c-Fos families and is regulated by the phosphorylation of c-Jun by the JNK kinase and c-Fos by c-Fos-regulating kinase (41Karin M. J. Biol. Chem. 1995; 270: 16483-16486Abstract Full Text Full Text PDF PubMed Scopus (2249) Google Scholar). The SRE element is found in the promoter region of c-Fos and is activated by the transcription factor Elk1, a ternary complex factor protein that binds SRE through direct DNA interaction and cooperation with the serum response factor. Elk1 can be phosphorylated and activated by either ERK or JNK kinases. Fig.1 A shows that RIP2 can activate both the AP-1 and SRE promoters. Expression of a kinase-deficient variant D146A, which eliminates the conserved catalytic base in the kinase subdomain VI, has a significantly reduced activity in both assays. RIP2 expression may increase AP-1 activity by directly activating the JNK pathway. Alternatively, as RIP2 can activate SRE promoters, AP-1 may be activated indirectly by the increased expression of c-Fos through the activation of the ERK pathway. To distinguish between these possibilities, we examined whether RIP2 could activate Elk1 or c-Junin vivo. We measured the ability of Elk1 or c-Jun (expressed as GAL4 fusion proteins) to activate a GAL4-regulated reporter in response to the increased expression of RIP2. Fig. 1 B shows that the expression of RIP2 led to the activation of Elk1 but not c-Jun indicating that RIP2 directly activates the ERK but not the JNK pathway. The extent of Elk1 activation is dependent on the level of RIP2 expression (Fig. 1 C) and also on the kinase activity of RIP2 (Fig. 1 D). The residual Elk1 activation resulting from increased expression of RIP2 (D146A) may be due in part to contributions made by other regions of RIP2 (see Fig.7 B). To determine how RIP2 may specifically activate Elk1, we examined whether RIP2 can activate and phosphorylate any of the major components of the ERK signaling pathway. Fig. 2 Ashows that RIP2 activated exogenously added ERK2 to phosphorylate MBPin vitro. Similar results were obtained with the addition of ERK1 (data not shown). No significant increase in MBP phosphorylation was observed subsequent to the addition of MEK1, suggesting that RIP2 activated ERK2 directly. In the control experiment, Raf1 induced the phosphorylation of MBP in vitro only with the addition and subsequent activation of purified unactivated MEK1 and ERK2. RIP2 was also able to phosphorylate ERK2 directly (Fig. 2 A, middle panel) but not MEK1 (data not shown but see Fig.6 D). The activation and phosphorylation of ERK2 appears to be mediated directly by the kinase activity of RIP2 since the RIP2(D146A) mutant failed to phosphorylate or activate ERK2 in a similar assay (Fig. 2 B). Western analysis of ERK2 with an antibody raised specifically against phospho-p44/42 MAP kinase (Thr-202/Tyr-212) revealed that RIP2, but not the D146A mutant, phosphorylated ERK2 on the activating TEY sites in vivo(Fig. 2 C). Furthermore, RIP2 was able to phosphorylate a kinase-deficient GST-ERK1(K71A) in vitro also in a manner dependent on the kinase activity of RIP2, suggesting that that increased phosphorylation of ERK was not due to its enhanced autophosphorylation activity (Fig. 2 D). These results indicate that RIP2 is an ERK kinase that can directly phosphorylate and activate ERK1 and ERK2. Ras and Raf1 are known to play central roles in regulating ERK activation. We then investigated whether Ras or Raf1 can influence the activation of ERK2 by RIP2 in vivo. Fig.3 shows that the expression of RIP2, Ras, or Raf1 independently activates ERK, whereas co-expression of RIP2 with Ras (Fig. 3 A) or with Raf1 (Fig. 3 B) further induced ERK2 activity. The cooperative interaction between RIP2 and Ras or between RIP2 and Raf1 suggests an activating interaction between these molecules. Since RIP2 activates ERK directly, Ras and Raf1 could possibly play a role in enhancing RIP2 activity toward ERK. The cooperative interactions between RIP2 and Ras or Raf1 suggest the possibility that RIP2 could physically interact with either of these molecules. Transient transfection and co-immunoprecipitation using anti-Raf1 antibodies revealed that Raf1 interacted with FLAG-RIP2 and RIP2(D146A) in vivo (Fig.4 A). The reduction in the amount of RIP2(D146A) that co-immunoprecipitated with Raf1 (as compared with RIP2) in Fig. 4 A may reflect a requirement for this region of the molecule for full interaction with Raf1. The specificity of this interaction was also confirmed by immunoprecipitating RIP2 using FLAG beads and performing Western analysis with Raf1 antibody (data not shown). Furthermore, Raf1 was found to interact only with FLAG-RIP2 but not with an unrelated protein FLAG-Nsp1 (42Lu Y. Brush J. Stewart T.A. J. Biol. Chem. 1999; 274: 10047-10052Abstract Full Text Full Text PDF PubMed Scopus (51) Google Scholar) (Fig.4 B). The binding of RIP2 to Raf1 was enhanced by the co-expression of constitutively active Ha-Ras (GTP-Ras), which contains an activating substitution (L61Q) that was previously shown to increase nucleotide exchange (GTP for GDP) as well as decrease GTP hydrolysis in Ras (43Feig L.A. Cooper G.M. Mol. Cell. Biol. 1988; 8: 3235-3243Crossref PubMed Scopus (679) Google Scholar). As shown in Fig. 4 C, the amount of RIP2 present in Raf1 immunoprecipitates increased with the amount of GTP-Ras that coincidentally interacted with Raf1. A conformational change in Raf1 as a consequence of its interaction with GTP-Ras (44Tzivion G. Luo Z. Avruch J. Nature. 1998; 394: 88-92Crossref PubMed Scopus (386) Google Scholar) may induce the increased affinity for RIP2. Conversely, increased expression of the dominant negative RasN17 decreased the amount of RIP2 that interacted with Raf1 (Fig. 4 D) consistent with the possibility that an active Raf1 is required to bind RIP2. The presence of RIP2 in the Ras-Raf1-RIP2 complex does not appear to be mediated by a Ras-RIP2 interaction as we could not detect any direct interaction between RIP2 and Ras by co-immunoprecipitation (data not shown). The Raf1-Rip2 interaction led us to examine whether Raf1 could directly phosphorylate and activate RIP2. First, we determined whether co-expression and co-immunoprecipitation of Raf1 with the kinase-inactive RIP2(D146A) would induce the phosphorylation of RIP2(D146A) in vitro when Raf1 is activated by GTP-Ras. Raf1 activation achieved through co-expression with increasing amounts of GTP-Ras led to an increased phosphorylation of RIP2(D146A) (Fig.5 A, panel a, lanes 3–5). The phosphorylation of RIP2(D146A) appears to be due to the kinase activity of Raf1 itself since the amount of phosphorylation associated with RIP2(D146A) was significantly reduced when the kinase-inactive Raf1(K375M) was used (Fig. 5 A, panel d). We also determined whether increasing Raf1 activation enhances the ability of RIP2 to activate ERK2 in vitro. Transiently expressed FLAG-RIP2 and Raf1 were co-immunoprecipitated in the presence or absence of GTP-Ras and assayed for ERK2 activation. As shown on Fig.5 B, Raf1 expression and activation by GTP-Ras further increased ERK2 activation by RIP2. This effect also appears to be mediated directly by the kinase activity of Raf1 since expression of Raf1(K375M) was significantly less effective in activating RIP2. Expression of GTP-Ras in the absence of Raf1 did not directly lead to an increase in RIP2 activity (Fig. 5 C) nor RIP2 expression (data not shown). These results therefore suggest that Raf1, when activated by GTP-Ras, can phosphorylate RIP2 and can further stimulate it to activate ERK2. Despite the interaction with Raf1, RIP2 does not appear to phosphorylate Raf1. Fig.6 A shows that transiently expressed Raf1 does not possess any discernible autophosphorylation activity (lane 2), but it becomes phosphorylated when constitutively active Ras L61Q (GTP-Ras) is co-expressed (lane 7). Although RIP2 appears to phosphorylate itself in Raf1 immunoprecipitates, increased binding of RIP2 to Raf1 did not cause any concomitant increase in the phosphorylation of Raf1 in vitro(lanes 3–6). The failure to phosphorylate Raf1 suggests that RIP2 does not activate Raf1. To examine this, we assayed Raf1 immunoprecipitates containing increasing amounts of RIP2 for their ability to activate exogenously added ERK2 in the presence (Fig. 6 B) or absence (Fig.6 C) of MEK1. There was significant phosphorylation of MBP by Raf1 only after Raf1 was activated by GTP-Ras and when assayed in the presence of both MEK1 and ERK2 (compare lanes 2 and7 in Fig. 6, B and C). In contrast, increased binding of RIP2 did not increase phosphorylation of Raf1 (Fig. 6 A) or the activation of Raf1 toward MEK1 (Fig.6 D). The slight increase in MBP phosphorylation detected with increasing RIP2 in Fig. 6, B and C, can be accounted for by the increase in the amount of RIP2 that co-immunoprecipitated with Raf1 and that activated ERK2 directly. That Raf1 is not activated is most clearly seen in Fig. 6 D where the Raf1 immunoprecipitates, in the presence of RIP2 but absence of GTP-Ras, have no detectable MEK1 phosphorylation activity. These results therefore suggest that RIP2 does not activate Raf1. RIP2 was earlier reported to interact with the TRAF1 and TRAF2 adaptor molecules that associate with members of the TNF receptor superfamily (38McCarthy J.V. Ni J. Dixit V. J. Biol. Chem. 1998; 273: 16968-16975Abstract Full Text Full Text PDF PubMed Scopus (361) Google Scholar, 39Thome M. Hofmann K. Burns K. Martinon F. Bodmer J.L. Mattmann C. Tschopp J. Curr. Biol. 1998; 8: 885-888Abstract Full Text Full Text PDF PubMed Google Scholar). TRAF2, in particular, has been shown to signal the activation of the JNK but not the ERK pathway from both TNFR1 and TNFR2 (28Reinhard C. Shamoon B. Shymala V. Williams L.T. EMBO J. 1997; 16: 1080-1092Crossref PubMed Scopus (252) Google Scholar). Results presented above indicate that RIP2 activates and interacts with members of the ERK pathway. As TNFα also activates ERK (4Belka C. Wiegmann K. Adam D. Holland R. Neulloh M. Hermann F. Kronke M. Brach M.A. EMBO J. 1995; 14: 1156-1165Crossref PubMed Scopus (91) Google Scholar, 5Winston B.W. Riches D.W. J. Immunol. 1995; 155: 1525-1533PubMed Google Scholar, 6Winston B.W. Lange-Carter C.A. Gardner A.M. Johnson G.L. Riches D.W. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 1614-1618Crossref PubMed Scopus (134) Google Scholar), it is possible that RIP2 could be involved in the activation of ERK by TNFα. To examine this, we expressed various kinase-deficient point and deletion mutants of RIP2 (Fig.7 A) and determined whether these would block the activating phosphorylation of ERK2 by TNFα through Western analysis using a phospho-specific p44/42 MAP kinase (Thr-202/Tyr-212) antibody. To determine specificity, we also examined whether the same RIP2 mutants could block the activation of ERK2 by EGF or of c-Jun by TNF. Fig. 7 B shows that stimulation of the cells by TNFα or EGF led to an increase in the activation or phosphorylation of ERK2 or c-Jun in vivo (lanes 1and 2). Expression of the different RIP2 variants alone did not induce ERK2 activation in unstimulated cells (lanes 3, 7, and 11). However, the increased expression of these variants significantly reduced the activation of ERK2 upon TNF stimulation (upper panel) but had only minimal effect on activation induced by EGF (middle panel). In addition, the dominant negative effects of these RIP2 mutants were only observed for TNF-induced ERK activation but not for c-Jun activation (lower panel). The dominant negative effect shown by the D146A mutant (upper panel, lanes 4–6) suggests that the kinase activity of RIP2 is required for TNF-dependent ERK activation. That the level of ERK2 activation in TNF-stimulated cells expressing only the CARD domain (455–541, lanes 12–14) was lower than in cells expressing both the intermediate and CARD domains (311–541,lanes 8–10) suggests that the intermediate domain of RIP2 may also participate in ERK signaling. Similarly, the more efficient blocking by the kinase deletion variants compared with that of the point mutant (D146A) indicates that other regions within the kinase domain may also contribute in transducing the signal. These results therefore underscore the importance of the kinase domain of RIP2 in mediating ERK2 activation by TNFα. RIP2 was originally isolated based on its homology to CARD and was shown to associate with members of the TNFR-1, CD40, and Fas signaling complexes and to induce NF-κB, JNK, and apoptosis. Like RIP, the induction of these responses by RIP2 does not appear to involve its kinase activity as kinase-inactive variants of RIP2 are still capable of engaging these pathways (38McCarthy J.V. Ni J. Dixit V. J. Biol. Chem. 1998; 273: 16968-16975Abstract Full Text Full Text PDF PubMed Scopus (361) Google Scholar, 39Thome M. Hofmann K. Burns K. Martinon F. Bodmer J.L. Mattmann C. Tschopp J. Curr. Biol. 1998; 8: 885-888Abstract Full Text Full Text PDF PubMed Google Scholar). We independently isolated RIP2 and have demonstrated that RIP2 functions as a novel activating MAPK kinase that may modulate ERK signaling by TNFα. First, RIP2 expression induces SRE-regulated gene expression (Fig. 1 A), Elk1 activation (Fig. 1 D), and ERK phosphorylation and activation (Fig. 2). All of these activities were significantly reduced when a kinase-inactive RIP2(D146A) variant was used. Second, RIP2 interacts with components of the ERK signaling pathway (Fig. 4) and cooperates with these molecules in promoting the activation of ERK2 (Fig. 3). Third, RIP2 mutants lacking a functional kinase activity can significantly reduce the activation of ERK2 by TNFα (Fig. 7). Despite having a high sequence similarity to the kinase domain of Raf1, RIP2 apparently behaves more like MEK1. RIP2 binds to and is activated by Ras-activated Raf1 (Fig. 5), and RIP2 appears to phosphorylate and activate ERK1 and ERK2 directly (Fig. 2). In contrast, RIP2 does not phosphorylate or activate Raf1 (Fig. 6) or MEK1 (Fig. 2 A). Although RIP2 possesses an active kinase activity even in the absence of any exogenous stimuli, it can be further activated by Ras-activated Raf1 (Fig. 5). This activation is also reflected in the association between Raf1 and RIP2 which is enhanced by activated Ras (Fig.4 C) and is diminished by a dominant negative mutant of Ras (Fig. 4 D). Although it is clear that TNFα can activate the ERK pathway, the role of Raf1 in this process remains controversial (33Muller G. Storz P. Bourteele S. Doppler H. Pfizenmaier K. Mischak H. Philipp A. Kaiser C. Kolch W. EMBO J. 1998; 17: 732-742Crossref PubMed Scopus (104) Google Scholar). Yao et al. (31Yao B. Zhang Y. Delikat S. Mathias S. Basu S. Kolesnick R. Nature. 1995; 378: 307-310Crossref PubMed Scopus (303) Google Scholar) have proposed that the secondary messenger ceramide, produced by TNF stimulation, can activate ceramide-activated protein kinase to phosphorylate and activate Raf1 directly. More recent studies, however, have shown that ceramide binds Raf1 directly but induces Raf1 to form an inactive complex (relative to MEK1 activation) with GTP-Ras (33Muller G. Storz P. Bourteele S. Doppler H. Pfizenmaier K. Mischak H. Philipp A. Kaiser C. Kolch W. EMBO J. 1998; 17: 732-742Crossref PubMed Scopus (104) Google Scholar). Furthermore, the ceramide-activated protein kinase-induced phosphorylation of Raf1 was mapped to Thr-268/269 which are Raf1 autophosphorylation sites rather than the known MEK1-activating phosphorylation sites (45Morrison D.K. Heidecker G. Rapp U.R. Copeland T.D. J. Biol. Chem. 1993; 268: 17309-17316Abstract Full Text PDF PubMed Google Scholar). It has been suggested that the phosphorylation of these sites may serve to redirect the substrate specificity of Raf1 to yet unknown substrates different from MEK1. This substrate may be RIP2. That kinase-deleted variants of RIP2 can significantly block ERK activation in response to TNFα suggests that RIP2 could be a major transducer of this pathway (Fig. 7 C). As Raf1 can phosphorylate and activate RIP2, it is possible that in the case of TNF signaling, either Raf1 bound to ceramide or Raf1 phosphorylated by ceramide-activated protein kinase could have its specificity shifted toward RIP2. It was recently shown that the adaptor protein Grb2 directly interacts with the TNF receptor in a TNF-dependent fashion (35Hildt E. Oess S. J. Exp. Med. 1999; 189: 1707-1714Crossref PubMed Scopus (64) Google Scholar). This complex consequently recruits SOS which leads to the activation of Ras and Raf1. This process is similar to that activated by receptor tyrosine kinases, although in this case, additional steps are apparently required to achieve full ERK activation. Our data suggest the possibility that recruitment of RIP2 by TRAFs, coupled to its activation by Raf1 within the TNF receptor complex, may fulfill at least some of the missing requirements. Furthermore, the use of RIP2 as an alternative to MEK1 may be to contribute to a faster and more specific signal transmission in TNF signaling to ERK. There are multiple MAPK cascades within a cell and the same subset of kinases can be used, yet different effector proteins are activated depending on the stimulus. There is increasing support for the concept that specific adaptor molecules are used to assemble and route these proteins to prevent or facilitate cross-talk between pathways (46Elion E.A. Science. 1998; 281: 1625-1626Crossref PubMed Scopus (120) Google Scholar). For example, kinase suppressor of Ras was shown to facilitate Ras signal transmission possibly by shuttling MEK1 from the cytoplasm to activated Raf1 at the membrane (47Denouel-Galy A. Douville E.M. Warne P.H. Papin C. Laugier D. Calothy G. Downward J. Eychene A. Curr. Biol. 1997; 8: 46-55Abstract Full Text Full Text PDF Scopus (135) Google Scholar, 48Therrien M. Michaud N.R. Rubin G.M. Morrison D.K. Genes Dev. 1996; 10: 2684-2695Crossref PubMed Scopus (208) Google Scholar, 49Yu W. Fantl W.J. Harrowe G. Williams L.T. Curr. Biol. 1997; 8: 56-64Abstract Full Text Full Text PDF Scopus (163) Google Scholar). Similarly, the adaptor protein MP1 appears to associate selectively with ERK1 and MEK1, and not MEK2 or ERK2, to enhance ERK1 activation (50Schaeffer H.J. Catling A.D. Eblen S.T. Collier L.S. Krauss A. Weber M.J. Science. 1998; 281: 1668-1671Crossref PubMed Scopus (384) Google Scholar). Whereas the kinase suppressor of Ras facilitates MEK1 activation by Ras and Raf1, a similar protein may be involved in RIP2 activation by Ras and Raf1. Although distinct signaling responses are induced by TNFα, functional interactions exist between these pathways. For example, both NF-κB and apoptosis are induced by TNFα, and one consequence of NF-κB activation is the prevention of apoptosis, perhaps through the TRAF-mediated suppression of caspase 8 (51Beg A.A. Baltimore D. Science. 1996; 274: 782-784Crossref PubMed Scopus (2931) Google Scholar, 52Liu Z. Hsu H. Goeddel D.V. Karin M. Cell. 1996; 87: 565-576Abstract Full Text Full Text PDF PubMed Scopus (1779) Google Scholar, 53Wang C.Y. Mayo M.W. Korneluk R.G. Goeddel D.V. Baldwin A.S. Science. 1998; 281: 1680-1683Crossref PubMed Scopus (2566) Google Scholar). A similar dichotomy may exist for RIP2. Thus RIP2 is pro-apoptotic via the interaction of its CARD domain with CLARP, caspase-1, or caspase-8 (37Inohara N. del Peso L. Koseki T. Chen S. Nunez G. J. Biol. Chem. 1998; 273: 12296-12300Abstract Full Text Full Text PDF PubMed Scopus (216) Google Scholar) and anti-apoptotic via activation of the ERKs (this report). The activation of the RIP2 kinase activity could positively regulate cell proliferation and survival, whereas negative regulators of RIP2 kinase could favor caspase activation and promote cell death. Whether and how RIP2 may coordinate the balance between life and death in response to TNF stimulation is an important question that will be addressed in future experiments. We thank Jennifer Brush for sequencing RIP2; Jim Ligos for graphics; Justin McCarthy and Vishva Dixit for providing the RIP2 deletion constructs; Ruey Bing Yang and Jamie Sheridan for sharing some plasmids and reagents; James Pan for stimulating discussion; and members of the Stewart laboratory for helpful discussion and technical support." @default.
• W2008025218 created "2016-06-24" @default.
• W2008025218 creator A5010721531 @default.
• W2008025218 creator A5013469580 @default.
• W2008025218 creator A5063862150 @default.
• W2008025218 date "1999-11-01" @default.
• W2008025218 modified "2023-10-13" @default.
• W2008025218 title "RIP2 Is a Raf1-activated Mitogen-activated Protein Kinase Kinase" @default.
• W2008025218 cites W135294775 @default.
• W2008025218 cites W1500815560 @default.
• W2008025218 cites W1502098090 @default.
• W2008025218 cites W1566737177 @default.
• W2008025218 cites W1587753447 @default.
• W2008025218 cites W162456380 @default.
• W2008025218 cites W1675086682 @default.
• W2008025218 cites W1888783223 @default.
• W2008025218 cites W1954176684 @default.
• W2008025218 cites W1964923016 @default.
• W2008025218 cites W1970161839 @default.
• W2008025218 cites W1972414794 @default.
• W2008025218 cites W1975870295 @default.
• W2008025218 cites W1977472414 @default.
• W2008025218 cites W1979595147 @default.
• W2008025218 cites W1983398917 @default.
• W2008025218 cites W1984113136 @default.
• W2008025218 cites W1986308149 @default.
• W2008025218 cites W1989762251 @default.
• W2008025218 cites W1990735654 @default.
• W2008025218 cites W1991760443 @default.
• W2008025218 cites W1995819749 @default.
• W2008025218 cites W2002507218 @default.
• W2008025218 cites W2011184275 @default.
• W2008025218 cites W2017472765 @default.
• W2008025218 cites W2025128734 @default.
• W2008025218 cites W2025548430 @default.
• W2008025218 cites W2029501678 @default.
• W2008025218 cites W2032417513 @default.
• W2008025218 cites W2032514624 @default.
• W2008025218 cites W2033403762 @default.
• W2008025218 cites W2036528355 @default.
• W2008025218 cites W2038212272 @default.
• W2008025218 cites W2043775652 @default.
• W2008025218 cites W2046078740 @default.
• W2008025218 cites W2057392977 @default.
• W2008025218 cites W2065257477 @default.
• W2008025218 cites W2067524077 @default.
• W2008025218 cites W2072243374 @default.
• W2008025218 cites W2075104267 @default.
• W2008025218 cites W2077490693 @default.
• W2008025218 cites W2084098251 @default.
• W2008025218 cites W2086419819 @default.
• W2008025218 cites W2089394364 @default.
• W2008025218 cites W2094334993 @default.
• W2008025218 cites W2102585554 @default.
• W2008025218 cites W2117669008 @default.
• W2008025218 cites W2118897660 @default.
• W2008025218 cites W2124202816 @default.
• W2008025218 cites W2126544407 @default.
• W2008025218 cites W2152445095 @default.
• W2008025218 cites W2473173223 @default.
• W2008025218 doi "https://doi.org/10.1074/jbc.274.47.33684" @default.
• W2008025218 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10559258" @default.
• W2008025218 hasPublicationYear "1999" @default.
• W2008025218 type Work @default.
• W2008025218 sameAs 2008025218 @default.
• W2008025218 citedByCount "90" @default.
• W2008025218 countsByYear W20080252182012 @default.
• W2008025218 countsByYear W20080252182013 @default.
• W2008025218 countsByYear W20080252182014 @default.
• W2008025218 countsByYear W20080252182015 @default.
• W2008025218 countsByYear W20080252182016 @default.
• W2008025218 countsByYear W20080252182017 @default.
• W2008025218 countsByYear W20080252182018 @default.
• W2008025218 countsByYear W20080252182019 @default.
• W2008025218 countsByYear W20080252182020 @default.
• W2008025218 countsByYear W20080252182022 @default.
• W2008025218 countsByYear W20080252182023 @default.
• W2008025218 crossrefType "journal-article" @default.
• W2008025218 hasAuthorship W2008025218A5010721531 @default.
• W2008025218 hasAuthorship W2008025218A5013469580 @default.
• W2008025218 hasAuthorship W2008025218A5063862150 @default.
• W2008025218 hasBestOaLocation W20080252181 @default.
• W2008025218 hasConcept C124160383 @default.
• W2008025218 hasConcept C132149769 @default.
• W2008025218 hasConcept C137361374 @default.
• W2008025218 hasConcept C159479382 @default.
• W2008025218 hasConcept C184235292 @default.
• W2008025218 hasConcept C185592680 @default.
• W2008025218 hasConcept C82495950 @default.
• W2008025218 hasConcept C86803240 @default.
• W2008025218 hasConcept C90934575 @default.
• W2008025218 hasConcept C95444343 @default.
• W2008025218 hasConcept C97029542 @default.
• W2008025218 hasConceptScore W2008025218C124160383 @default.
• W2008025218 hasConceptScore W2008025218C132149769 @default.
• W2008025218 hasConceptScore W2008025218C137361374 @default.
• W2008025218 hasConceptScore W2008025218C159479382 @default.
• W2008025218 hasConceptScore W2008025218C184235292 @default.

• next